Nanocarriers as Potential Drug Delivery Candidates for Overcoming the Blood-Brain Barrier: Challenges and Possibilities.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
09 Jun 2020
09 Jun 2020
Historique:
received:
07
04
2020
accepted:
18
05
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
The design of a drug that successfully overcomes the constraints imposed by the blood-brain barrier (BBB, which acts as a gatekeeper to the entry of substances into the brain) requires an understanding of the biological firewall. It is also of utmost importance to understand the physicochemical properties of the said drug and how it engages the BBB to avoid undesired side effects. Since fewer than 5% of the tested molecules can pass through the BBB, drug development pertaining to brain-related disorders takes inordinately long to develop. Furthermore, in most cases it is also unsuccessful for allied reasons. Several drug delivery systems (DDSs) have shown excellent potential in drug delivery across the BBB while demonstrating minimal side effects. This mini-review summarizes key features of the BBB, recapitulates recent advances in our understanding of the BBB, and highlights existing strategies for the delivery of drug to the brain parenchyma.
Identifiants
pubmed: 32548442
doi: 10.1021/acsomega.0c01592
pmc: PMC7288355
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
12583-12595Subventions
Organisme : NIGMS NIH HHS
ID : RL5 GM118969
Pays : United States
Organisme : NIGMS NIH HHS
ID : TL4 GM118971
Pays : United States
Organisme : NIGMS NIH HHS
ID : UL1 GM118970
Pays : United States
Informations de copyright
Copyright © 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Cells. 2018 Mar 23;7(4):
pubmed: 29570659
Int J Pharm. 2017 Jun 30;526(1-2):413-424
pubmed: 28495580
Nanoscale. 2017 Oct 19;9(40):15434-15440
pubmed: 28976512
JCI Insight. 2017 Apr 6;2(7):e90133
pubmed: 28405611
Drug Metab Dispos. 2002 May;30(5):479-82
pubmed: 11950774
Biomolecules. 2019 Aug 01;9(8):
pubmed: 31374911
Ther Deliv. 2010 Oct;1(4):483-8
pubmed: 22833960
J Control Release. 2017 May 10;253:165-171
pubmed: 28322975
J Funct Biomater. 2019 Jan 08;10(1):
pubmed: 30626094
Front Pharmacol. 2018 Jul 17;9:790
pubmed: 30065653
Curr Drug Targets. 2015;16(14):1671-81
pubmed: 26601723
Molecules. 2018 Aug 27;23(9):
pubmed: 30150595
ACS Appl Mater Interfaces. 2015 Sep 9;7(35):19798-808
pubmed: 26291070
Eur J Pharm Biopharm. 2017 Oct;119:253-263
pubmed: 28652141
Expert Opin Drug Deliv. 2009 Mar;6(3):211-25
pubmed: 19290842
J Control Release. 2018 Jan 28;270:290-303
pubmed: 29269142
J Control Release. 2017 Mar 10;249:173-182
pubmed: 28137632
Nanoscale. 2020 Feb 7;12(5):2946-2960
pubmed: 31994576
Pharm Res. 2009 Nov;26(11):2486-94
pubmed: 19774344
Drug Deliv. 2017 Nov;24(1):346-357
pubmed: 28165821
Nanoscale. 2019 Mar 28;11(13):6297-6306
pubmed: 30882825
Fluids Barriers CNS. 2011 Jan 18;8(1):3
pubmed: 21349151
Int J Pharm. 2009 Jun 22;375(1-2):89-96
pubmed: 19481694
Acta Pharm Sin B. 2020 Feb;10(2):239-248
pubmed: 32082970
Ann Med. 2007;39(3):219-28
pubmed: 17457719
Nanoscale. 2018 Sep 20;10(36):16962-16983
pubmed: 30182106
Cell Tissue Res. 2019 Jan;375(1):287-293
pubmed: 30535799
Environ Sci Technol. 2018 Dec 18;52(24):14445-14451
pubmed: 30486644
Front Pharmacol. 2019 Nov 13;10:1348
pubmed: 31798453
Nanomedicine (Lond). 2014 Feb;9(2):221-35
pubmed: 23834501
Nanomedicine. 2011 Oct;7(5):551-9
pubmed: 21658472